
Ramprasad Gadi  
*Einstein Medical Center and Jefferson Medical College*

Aman Amanullah  
*Einstein Medical Center and Jefferson Medical College*

Vincent M. Figueredo  
*Einstein Medical Center and Jefferson Medical College*

Follow this and additional works at: [https://jdc.jefferson.edu/cardiologyfp](https://jdc.jefferson.edu/cardiologyfp)

Part of the [Cardiology Commons](https://jdc.jefferson.edu/cardiologyfp)

Let us know how access to this document benefits you

**Recommended Citation**

[https://jdc.jefferson.edu/cardiologyfp/33](https://jdc.jefferson.edu/cardiologyfp/33)

This Article is brought to you for free and open access by the Jefferson Digital Commons. The Jefferson Digital Commons is a service of Thomas Jefferson University's [Center for Teaching and Learning (CTL)](https://ctl.jefferson.edu). The Commons is a showcase for Jefferson books and journals, peer-reviewed scholarly publications, unique historical collections from the University archives, and teaching tools. The Jefferson Digital Commons allows researchers and interested readers anywhere in the world to learn about and keep up to date with Jefferson scholarship. This article has been accepted for inclusion in Division of Cardiology Faculty Papers by an authorized administrator of the Jefferson Digital Commons. For more information, please contact: JeffersonDigitalCommons@jefferson.edu.
HDL-C: DOES IT MATTER?  
An update on novel HDL- directed  
pharmacological strategies

Ramprasad Gadi, MD, ABCL  
Aman Amanullah, MD PhD  
Vincent M. Figueredo, MD

Einstein Institute for Heart and Vascular Health, Albert Einstein Medical  
Center, and Jefferson Medical College, Philadelphia, PA

Running head: High density lipoprotein (HDL-C) and cardiovascular  
disease

Key words: high density lipoprotein (HDL-C), HDL-C therapeutics,  
cardiovascular, coronary artery disease

Disclosures: no conflict of interest

Address correspondence to: Dr.Ramprasad Gadi, MD  
Einstein Institute for Heart and Vascular Health  
5501 Old York Road, Levy 3  
Philadelphia, PA 19141  
TEL: 215-431-9404  
FAX: 215-405-3781  
E-mail: ram.gadi@gmail.com
HDL THERAPEUTICS ABSTRACT

It has long been recognized that elevated levels of low-density lipoprotein cholesterol (LDL-C) increase the risk of cardiovascular disease (CHD) and that pharmacologic therapy to decrease LDL-C significantly reduces cardiovascular events. Despite the effectiveness of statins for CHD risk reduction, even optimal LDL-lowering therapy alone fails to avert 60% to 70% of CHD cases. A low plasma concentration of high-density lipoprotein cholesterol (HDL-C) is also associated with increased risk of CHD. However, the convincing epidemiologic data linking HDL cholesterol (HDL-C) to CHD risk in an inverse correlation has not yet translated into clinical trial evidence supporting linearity between HDL-C increases and CHD risk reduction. It is becoming clear that a functional HDL is a more desirable target than simply increasing HDL-C levels. Discoveries in the past decade have shed light on the complex metabolic and antiatherosclerotic pathways of HDL. These insights, in turn, have fueled the development of new HDL-targeted drugs, which can be classified according to four different therapeutic approaches: directly augmenting the concentration of apolipoprotein A-I (apo A-I), the major protein constituent of HDL; indirectly augmenting the concentration of apo A-I and HDL cholesterol; mimicking the functionality of apo A-I and enhancing reverse cholesterol transport. This review discusses the latest in novel HDL directed therapeutic strategies.
TOPIC: HDL C – Does it matter?
An update on novel HDL-C directed therapeutic strategies

INTRODUCTION:

An estimated 16.3 million persons, or 7.6% of the United States population, have coronary heart disease (CHD) (1). Cardiovascular disease is responsible for 811,940 or 32.8% of all deaths in the United States on an annual basis (1). Focused risk reduction therapies are indicated for patients with CHD and those at significant risk to reduce events and improve survival rates.

The relationship between low density lipoprotein cholesterol (LDL-C) and high density lipoprotein cholesterol (HDL-C) and the development of CHD is widely acknowledged.

In addition, the cardiovascular benefit for lowering LDL-C for those with CHD is now well established (2). Current treatment strategies for reducing CHD risk are insufficient to prevent most CHD events and suggest therapies for increasing HDL-C in addition to reducing LDL-C are necessary to prevent CHD events (3-5).
However, the convincing epidemiologic data linking HDL-C and CHD risk has not yet translated into significant clinical trial evidence supporting linearity between HDL-C increases and CHD risk reduction. The recent negative results obtained in the ILLUMINATE and AIM-HIGH trials suggest that HDL-C increases may not always be beneficial (41, 63). The results from these studies have led us to more questions than answers in our quest to reduce CHD events by improving HDL-C.

**HDL FUNCTION**

The knowledge of an inverse relationship between plasma levels of HDL-C and rates of CHD gained from epidemiological studies has long been held as a near guarantee that interventions that increase HDL-C will reduce CHD risk (6, 7). However, investigators in clinical trials have so far failed to convey a mandate to increase HDL-C levels by a specific degree or beyond a specific threshold to achieve protection against CHD events (8). Moreover, both genetic studies and clinical trials support the idea that, in some circumstances, HDL-C levels may behave opposite to what is predicted by the Framingham assessment model (9, 10). For example, carriers of the apoAI Milano mutation present with low levels of HDL-C but are resistant to atherosclerosis (11,12), whereas subjects with cholesteryl ester transfer protein (CETP) deficiency have high HDL-C levels but are not patently
protected against atherosclerosis (13-16). In addition, common polymorphisms in the CETP and hepatic lipase genes linked to elevated HDL-C levels are associated with increased cardiovascular events (17, 18).

These apparently contradictory findings may be explained by the notion that a “functional” HDL, rather than high plasma HDL-C concentration, is needed for a therapeutic effect. HDL functionality and HDL-C concentrations likely go hand in hand in most people, but may diverge in the presence of specific mutations, in some disease states, or by the action of drugs (19-21). Therefore, newer therapies need to target HDL functionality rather than only HDL-C concentrations in the blood.

Mutations affecting the function of an enzyme rarely are linked to improved metabolism or health. Polymorphisms of both the CETP gene, leading to high HDL-C levels through reduced cholesterol exchange, and the hepatic lipase gene, leading to high HDL-C levels through impaired lipolysis, have been linked to increased risk for CHD (17, 18). Indeed, a dysfunctional HDL is more likely associated with high, rather than low, HDL-C levels because it may often reflect altered recycling of the mature plasma HDL particle. Because of its high concentration, carrying a dysfunctional HDL may be more dangerous for vascular
health than having low levels of functional HDL. Ansell et al (22) showed that patients with CHD and HDL-C greater than 85 mg/dL carry dysfunctional HDL. A recent analysis of The Incremental Decrease in Endpoints through Aggressive Lipid Lowering trial (IDEAL) and European Prospective Investigation of Cancer-Norfolk observational study determined that the classic inverse correlation between HDL-C and CHD risk is not sustained when evaluating subjects with HDL greater than 70 mg/dL who appear to have increased CHD risk even when on statin therapy (23). CHD risk was also increased by the presence of large HDL particles, suggesting that dysfunctional reverse cholesterol transport with accumulation of lipid-loaded HDL in the plasma and high HDL-C levels is a pro-atherogenic condition (23). Thus it is becoming clear that a functional HDL is a more desirable target than simply increasing HDL-C levels.

A reason why so much emphasis is placed on the plasma HDL-C level as a predictor of vascular health is because it theoretically represents reverse cholesterol transport (RCT), the system in charge of removing cellular cholesterol excesses from tissue sites of accumulation (24). The sub endothelial space of the medium caliber artery is the most important tissue in this regard because accumulation of cholesterol-rich cells causes atheroma formation and the real target of therapy is to activate cholesterol exit.
from this very site. Because the essential function of HDL occurs in the extravascular space, and not in the plasma compartment, it is likely that plasma HDL-C levels have a limited power to predict RCT functionality in the target tissue. Moreover, HDL influences the atherogenic process not only through cholesterol extraction but also through anti-inflammatory and antioxidant properties (25).

However, what we test in plasma is almost exclusively the amount of cholesterol that the HDL has collected from tissues other than the arterial wall. If inappropriate amounts of HDL penetrate the plaque or if the load of oxidized plaque lipids destabilizes HDL function, it is obvious that plasma HDL-C levels may be more and more disconnected from CV risk prediction. This new knowledge on dysfunctional HDL has been termed a paradox because functionality is not directly linked to changes in HDL-C plasma concentrations (26). However, there is nothing paradoxical about it. RCT is necessary to remove excess cholesterol from peripheral cells in all tissues, a biologically essential function even if cholesterol trapping in the artery wall and the atherosclerotic process were not a common occurrence in humans. Plasma HDL-C levels represent the balance between generation of mature HDL particles in the circulation and loss of lipid cargo via both HDL receptor (scavenger receptor type BI [SR-BI])-mediated transfer to hepatocytes and CETP-mediated transfer to other lipoproteins. (27,28)
Loss of lipid cargo is a desirable event because it leads to unloading of cholesterol and oxidized phospholipids in the liver and to the rebirth of the HDL particle for a new round of cholesterol acquisition. Therefore, a high HDL-C level may mean enhanced production of mature HDL in the plasma compartment (a good thing) or reduced loss of lipid cargo (not a good thing). Conversely, a low HDL-C level may signal increased loss of lipid cargo (a good thing) or reduced peripheral cholesterol collection (not a good thing).

**HDL METABOLISM**

HDL starts its life cycle as poorly lipidated apolipoprotein A1 (apoA1), which has a mandate to collect cellular cholesterol to avoid receptor-mediated degradation in the renal tubule (29, 30) (see Fig 1). ApoA1 collects membrane cholesterol through multiple mechanisms, including specific ones requiring physical engagement with transmembrane lipid channels such as ATP-binding cassette transporter A1 (ABCA1), ATP-binding cassette transporter G1 (ABCG1) and scavenger receptor class B member (SR-BI) (31). It is believed that ABCA1 transfers phospholipids and cholesterol to the nascent HDL (32), whereas ABCG1 connects with larger HDL particles (33). SR-BI (also known as the hepatic HDL receptor) contributes significantly to lipid transfer from cells overloaded with cholesterol, such as arterial
macrophages, and therefore may play a central role in atherogenesis (34). As free (unesterified) cholesterol translocates across the cell membrane, HDL esterifies it by adding a fatty acid chain via the action of lecithin cholesterol acyl-transferase (LCAT) (31). The nonpolar cholesteryl esters are then stored in the particle core. The core expansion leads to compositional maturation, yielding particles that predominate in plasma HDL. This sequence of changes means that HDL is heterogeneous in size because of variations in total lipid cargo and in the array of lipoproteins, enzymes, and other functional proteins that can exist on its surface (35).

In the plasma compartment the mandate of the mature HDL switches from cholesterol acquisition to cholesterol delivery. This is achieved mainly via cholesteryl ester transfer protein (CETP)-mediated transfer of cholesterol to triglyceride-rich lipoproteins and via SR-BI mediated unloading of the cholesterol cargo in the liver. Plasma HDL that eliminates its lipid cargo can initiate a new cycle of peripheral cholesterol acquisition. This “reverse cholesterol transport-centric” view of HDL also encompasses the notion that its powerful anti-oxidant and anti-inflammatory effects are linked to the collection and removal of oxidized lipids from both cellular membranes and LDL in the arterial wall (36).

NONPHARMACOLOGIC APPROACHES FOR RAISING HDL
The National Cholesterol Education Program (NCEP) Adult Treatment Panel III (ATP III) increased the definition of low HDL cholesterol from 35mg/dl to 40mg/dl (37). Low HDL-C is also an important component of the definition for metabolic syndrome, with cut points of 40mg/dl for men and 50mg/dl for women. The NCEP ATP III guidelines state that therapeutic lifestyle changes are the initial intervention for increasing HDL cholesterol. These therapeutic lifestyle change measures include reducing the dietary intake of cholesterol, increasing the use of plant stanols/sterols and fiber to lower LDL cholesterol, and moderating intake of calories and increasing physical activity to maintain desirable weight and cardiovascular fitness. Weight loss and smoking cessation are also advocated and can aid in raising serum levels of HDL. Dietary modification, including ingestion of omega-3 fatty acids via fish consumption or fish oil supplementation, has also demonstrated an effect in raising HDL-C. When therapeutic lifestyle changes are not adequate to increase serum HDL-C, pharmacologic therapy is often recommended.

**PHARMACOLOGIC THERAPY**

When therapeutic lifestyle changes are not adequate to achieve target goals, several pharmacologic therapy options exist for the management of low HDL-C (Table 1). It is well established that 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase
inhibitors (statins) lower LDL-C, which significantly affects cardiovascular morbidity and mortality (2). Other non-LDL lipid effects of statins, including decreasing triglycerides and raising HDL-C, may also contribute to the risk reduction. Additional therapies with significant LDL lowering effects, such as fibrates and niacin, which lower triglycerides and raise HDL-C, also have been shown to reduce CHD events despite less potent effects on reducing LDL (38). As highlighted in the NCEP ATP III guidelines, consideration should be given to combination therapy with a fibrate or nicotinic acid in addition to a statin for high-risk patients with a low HDL-C level (see Fig 2).

**STATIN THERAPY**

First-line management of dyslipidemia in patients with cardiovascular disease is achieved with statin therapy. In patients with low HDL-C, statins are very effective in reducing the absolute cardiovascular event rate (2). However, the residual risk of CHD events remains high. Statins typically increase HDL-C levels by approximately 5% to 10%. Although the mechanism(s) by which statins raise HDL-C remains unclear, statins appear to reduce the supranormal rates of endogenous CETP-mediated cholesteryl ester transfer from HDL by decreasing the number of Apo B lipoprotein available to accept cholesteryl ester from HDL. Statins also appear to enhance hepatic Apo Al production, which may not occur with high-dose atorvastatin (80 mg) in which there is
less HDL-C increase compared with similar LDL-C lowering by simvastatin or rosuvastatin. The clinical relevance of the difference in the HDL-C increase between atorvastatin 80 mg and rosuvastatin 40 mg is being tested in the Study of Coronary Atheroma by Intravascular Ultrasound: Effect of Rosuvastatin Versus Atorvastatin (SATURN) trial, an intravascular ultrasound (IVUS) trial measuring plaque volume in CHD patients (39).

**NIACIN**

Niacin, or nicotinic acid, is a soluble B vitamin that has favorable effects on all major lipid subfractions but has limited use due to its side-effect profile. Niacin was one of the first lipid-altering drugs to demonstrate a reduction in CHD events in the Coronary Drug Project (40). At present, niacin is identified as the most effective approved for raising HDL-C. In clinical studies, niacin has been demonstrated to lower LDL by 10% to 20%, triglyceride (TG) by 20% to 40%, and Lp (a) by 10% to 30%, as well as raise HDL by 15% to 30% (40). Niacin appears to increase HDL-C by decreasing the hepatic uptake of Apo AI, thereby delaying catabolism (41). Despite niacin being widely used in the management of dyslipidemia, the side effect of flushing of the face and upper body can affect compliance to therapy. Flushing has been attributed as the major reason for discontinuation of therapy, estimated at rates as high as 25% to 40% The flushing that is induced
by niacin is caused by the subcutaneous release of prostaglandin D2 (PGD2), which is mediated by niacin’s action as a pharmacologic ligand for the adipocyte and macrophage G protein coupled nicotinic acid receptor, GPR109A (42). The cutaneous vasodilation skin flush typically starts in the face with a deep red coloration, usually accompanied by an intense feeling of warmth and itching, with occasional extension to the arms and chest. Although the duration of the flushing is generally less than 1 hour, the unpleasant sensation for patients can often affect compliance and lead to therapy discontinuation. Moderate doses of prostaglandin inhibitors have been demonstrated to reduce the cutaneous flushing response from niacin (43). Several additional strategies for reducing niacin induced flushing include regular consistent dosing, use of extended-release formulations, patient education, dosing with meals or at bedtime, and avoidance of alcohol, hot beverages, spicy foods, and hot baths or showers close to or after dosing. In comparison with immediate release niacin, extended-release niacin results in reduced flushing as it is taken once a day at bedtime, when most flushing symptoms will occur when the patient is sleeping. However, the side effect profile includes the potential for liver toxicity (44). Other side effects include rash, flushing, gastrointestinal problems, worsening of esophageal reflux and gout, and headache (44).
STATIN - NIAalin COMBINATION THERAPY

Combination therapy with a statin and niacin has been used to reduce residual cardiovascular risk after statin use by targeting both the lowering of LDL-C and increasing low HDL-C. Several clinical trials using either immediate-release or extended-release niacin have demonstrated the efficacy and safety of this combination therapy in inhibiting the development of atherosclerosis (45). The Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol (ARBITTER) 2 trial demonstrated that the addition of extended-release niacin to statin therapy resulted in an increase in HDL-C of 21% and slowed the progression of atherosclerosis as measured by a change in carotid intima-media thickness (CIMT), as compared with statin therapy alone in patients with known CHD and low HDL-C levels (45). Although the ARBITER 2 trial showed slowing of progression of atherosclerosis, whether this translates to reduction of CHD events remains unclear.

The Atherothrombosis Intervention in Metabolic Syndrome with Low HDL/High Triglycerides: Impact on Global Health (AIM-HIGH) trial was the first large-scale outcomes study to evaluate the impact of adding extended-release niacin to statin therapy (simvastatin) in patients with established coronary artery disease (46). The study was designed to
test whether or not increasing HDL-C and lowering triglycerides in patients with low HDL-C and high triglycerides will reduce the risk of recurrent cardiovascular events in patients whose LDL-C was already within a desirable range with statin therapy.

AIM-HIGH enrolled 3414 participants in the US and Canada, who were all prescribed simvastatin and then randomized to either high-dose, extended-release niacin in gradually increasing doses up to 2000 mg per day (n=1718) or placebo (n=1696). Of the participants, 515 were given a second LDL-cholesterol-lowering drug, ezetimibe (Zetia, Merck/Schering-Plough), in order to maintain LDL-cholesterol levels at the target range between 40 and 80 mg/dL.

The primary end point for AIM-HIGH was a composite defined as time to first occurrence of any of the following: fatal or nonfatal myocardial infarction, ischemic strokes, hospitalizations for acute coronary syndrome or symptom driven coronary or cerebral revascularization procedures. Background therapy for all risk factors (blood pressure, blood glucose) was rigorous and met the goals set forth in the guidelines for high-risk patients. The addition of niacin to half of the patients did provide incremental HDL-C elevation and triglyceride reduction. However, the National Heart, Lung, and Blood Institute halted the trial prematurely because continuing was deemed futile after interim analyses showed no significant difference in adverse
outcomes between the two groups (249 primary outcome events [15%] in the simvastatin arm and 262 [15%] in the simvastatin/niacin arm; hazard ratio 1.053, 97.5% CI: 0.885-1.252; P=0.561). Moreover, investigators observed an excess hazard for ischemic stroke (28 vs. 12) that was numerically, though not statistically, significant in the group receiving niacin. Because of the small difference between treatment arms and the early termination of the trial, AIM-HIGH was underpowered to prove the hypothesis that niacin therapy may be beneficial in a secondary prevention population with controlled LDL-C. Therefore, the results of the study cannot be extrapolated to all patients with low HDL or all patients with uncontrolled LDL. The findings of AIM-HIGH will require careful study to determine if there are specific reasons for the failure of niacin to provide incremental risk reduction in this population of patients. The entire question of emerging science related to modulation of HDL in blood plasma is still being evaluated as new therapies beyond niacin are being developed. Ongoing pharmaceutical outcomes studies such as HPS2-THRIVE with over 25,000 patients may provide more insight regarding the efficacy of niacin in combination with statins to reduce CHD events.

The Heart Protection Study 2 Treatment of HDL to Reduce the Incidence of Vascular Events (HPS-2-THRIVE) is another large international trial of high-dose, extended-release niacin with simvastatin alone or in combination with ezetimibe in patients with
established cardiovascular disease. The study is still ongoing, with results expected in 2013 (47)

STATIN-FIBRATE COMBINATION THERAPY

Statin-fibrate combination therapy is effective in reducing LDL-C and TG, and in increasing HDL-C. Fibrates are peroxisome proliferator-activated receptor-alpha (PPAR-a) ligands that lead to increased lipoprotein lipase expression and decreased Apo CIII expression. This results in enhanced catabolism of TG-rich particles. The expression of Apo AI and A-II are also increased by fibrates, with a net result of decreasing hypertriglyceridemia and increasing HDL-C. Due to these effects, fibrate combination therapy is used for patients with hypertriglyceridemia and low HDL. Statin-fibrate combination use is restricted, due to reports of rhabdomyolysis that mainly involved gemfibrozil and cerivastatin, which was voluntarily withdrawn from the market worldwide in 2001 after reports of fatal rhabdomyolysis.

Fenofibrate or fenofibric acid is the fibrate of choice when used in combination with a statin because each is associated with a lower risk of myopathy than gemfibrozil. Several recent studies have demonstrated the efficacy and safety of fenofibric acid and statin
therapy in patients with mixed dyslipidemia in reducing triglycerides and raising HDL-C compared with statin monotherapy.

**NOVEL HDL-C DIRECTED THERAPEUTIC STRATEGIES**

There are four different therapeutic approaches to improve HDL-C (see Table 2):

1. Directly augmenting the concentration of apolipoprotein A-I (apo A-I), the major protein constituent of HDL
2. Indirectly augmenting the concentration of apo A-I and HDL-C
3. Mimicking the functionality of apo A-I
4. Enhancing reverse cholesterol transport.

**1. Directly Augmenting Apo A-I Levels**

**Recombinant HDL:** Lipid-poor apo A-I, also termed nascent HDL or preβ-HDL, initiates reverse cholesterol transport by activating macrophage (ABCA1) and accepting effluxed cholesterol. From a pharmacodynamic standpoint, direct augmentation of lipid-poor apo A-I concentration arguably represents the most validated HDL-related therapeutic approach in terms of anti-atherogenic potential.

Lipid-poor apo A-I–phospholipid complexes, sometimes referred to as recombinant HDL (rHDL), have been studied extensively in animals and
in preliminary studies in humans. Preclinical studies have demonstrated that the administration of apo A-I is associated with the inhibition or regression of atherosclerosis (51-54), enhanced macrophage-specific reverse cholesterol transport (55) and the inhibition of vascular inflammatory pathways (56). Moreover, short exploratory clinical studies of rHDL infusion have yielded decreases in coronary atherosclerosis, as assessed by coronary imaging, comparable with those obtained with long-term statin use at doses associated with improved clinical outcomes. These findings support the therapeutic potential of intravenous apo A-I infusion (57, 58).

**ApoA-1 Milano:** The apo A-I Milano mutation was first identified in a cohort of Italian patients who exhibited a decreased prevalence of atherosclerosis despite very low levels of HDL-C (10–20 mg/dl) (53). The effects of apo A-I Milano complexed with phospholipid (1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine), also known as ETC-216, have been studied in animals and humans (58). In support of an anti-atherogenic activity, infusions of ETC-216 in rabbit and mouse models of atherosclerosis were associated with considerable reductions in the lipid and macrophage content of plaque (60-62).

In a small clinical study of 47 patients with acute coronary syndrome, five weekly doses of 15–45 mg/kg of ETC-216 significantly reduced
total atheroma volume by 14.1 mm³ compared with baseline (4.2%; \( P < 0.001 \)), as measured by coronary intravascular ultrasonography (IVUS) (58). Total atheroma volume did not change significantly with the administration of placebo (-0.2 mm³; \( P = 0.97 \)).

**Wild type Apo A-I:** Human plasma derived wild-type apoA-1 linked to soybean phospholipid (CSL111) was infused at 40 mg/kg per infusion in humans in a small proof of concept trial (63). Five weekly infusions did not show a significant benefit on coronary plaque progression in comparison with placebo. However, when compared with pretreatment baseline, apoA-1 recipients showed regression in contradistinction to the placebo arm (63). The 80 mg/kg per infusion regimen was abandoned because of hepatic toxicity even though a single infusion of 80 mg/kg, in an unrelated study, was shown to favorably change femoral artery plaque composition (64). Overall, short-term infusion of synthetic HDL (containing apo A-I Milano or wild-type apoA-1) holds considerable promise as a potential strategy for rapid plaque remodeling and stabilization that could later be sustained with the use of orally LDL-C lowering and HDL-C raising agents, or even possibly repeated infusions. However, this requires further study.

**Autologous Delipidated HDL:** Another novel technique for increasing HDL-C involves the collection of 1 L of plasma by apheresis.
The technique includes over 2 hours of apheresis followed by selective lipid removed from HDL using organic solvents to produce lipid-poor pre-b HDL. The lipid-poor pre-b HDL, which is a more efficient acceptor of cholesterol, is then reinfused back into the patient. In a small human trial involving 28 patients with acute coronary syndrome, 7 weekly treatments resulted in a 5.2% decrease in atheroma volume compared with baseline (65). Small clinical trials using intravascular ultrasound of the coronary arteries showed a similar 3.5% to 5% decrease in atheroma volume compared with baseline, but due to the small sample sizes were not statistically significantly different from placebo.

2. Indirectly Augmenting Apo A-1 Levels

**Oral Upregulator of Endogenous Apo A-1:** RVX-208, an oral upregulator of endogenous Apo A-1 selectively induces nuclear transporter factors which in turn induces hepatic and intestinal production of Apo AI. This compound significantly increases HDL-C by more than 40% in monkeys, and the serum of treated animals was shown to enhance cholesterol efflux from foam cells (66). Significant increases in total plasma Apo AI were demonstrated in a small short-term human trial, but most of the increase was in pre-b HDL. RVX-208 was the first oral small molecule that stimulates Apo AI production to enter phase 2 trials.
**Niacin Receptor Agonists**

Niacin, the first antidyslipidemic agent identified, remains the most potent drug in use for increasing levels of HDL-C and apo A-I. However, the side effect of flushing of the face and upper body reduces compliance and leads to discontinuation of therapy in up to 25% to 40% of patients (44). The discovery of the niacin receptor GPR109A90 promised to usher in a new era in which the molecular mechanisms underlying the effects of niacin on lipids, and its adverse effects could be clearly defined (67). Co-administration of the DP1 antagonist laropiprant reduces the incidence of the skin-related adverse effects of niacin (68). However, flushing still occurs in over half of the patients, and discontinuation of niacin treatment owing to severe skin-related symptoms remains a problem (69). A study in mice implicated keratinocyte-produced prostaglandin, PGE2 as a key mediator of niacin-induced skin flushing, suggesting that this molecule might be another potential target to minimize flushing (70, 71).

3. **Mimicking Apo A-I Functionality**

Another HDL-directed therapeutic approach utilizes small peptides that mimic one or more of the functions of apo A-I (72, 73). The most well-studied apo A-I mimetic, 4F, consists of 18 amino acids designed to share the lipid-binding properties of apo A-I through a common secondary structure, the class A amphipathic helix (74). The only
reported human study of D-4F to date hints at the possibility of a benefit for this compound in humans (75). Compared with HDL isolated from individuals who received placebo, HDL isolated from individuals treated with a single 300 mg or 500 mg dose of unformulated D-4F increased the inhibition of LDL-induced monocyte chemotaxis in cultures of human aortic endothelial cells. As in animal studies, neither changes in apo A-I or HDL-C levels nor serious toxicity were observed in treated individuals.

4. Enhancing reverse cholesterol transport

CETP Inhibitors

CETP plays an important role in cholesterol metabolism, as it is responsible for the transfer of cholesteryl esters from HDL-C to VLDL-C and LDL-C (see Figure 1). CETP is a very large protein and has a hydrophobic tunnel across the molecule that can accommodate neutral lipid. CETP is a shuttle-type structure that promotes an equal mass gradient transfer of triglyceride for cholesterol ester between HDL and Apo-B lipoprotein (76). CETP plays an important role in maintaining a uniform distribution throughout the bloodstream and moves triglycerides where they are high (i.e., VLDL-C) to where they are low (HDL-C and LDL-C) in exchange for an equal mass gradient of cholesterol ester. Animals that lack CETP have very high HDL-C and very low LDL-C. CETP is important in modulating HDL size by
redistributing cholesterol ester from triglyceride-rich particles into HDL particle. The triglyceride-enriched HDL is further acted on by hepatic lipase to form a smaller dense HDL that is more rapidly catabolized.

CETP is also involved in transporting triglycerides in exchange for cholesterol ester from triglyceride-rich particles to LDL. LDL becomes triglyceride enriched and further hydrolyzed by the lipases to form a small dense atherogenic LDL. Theoretically inhibition of CETP should therefore result in beneficial effects on HDL-C and LDL-C which could translate into decreased atherogenesis and reduced cardiovascular events.

In the Investigation of Lipid Level Management to Understand its Impact in Atherosclerotic Events (ILLUMINATE) which involved patients receiving atorvastatin were randomized to torcetrapib or placebo (77). Torcetrapib worsened the primary combined cardiovascular end point of death from coronary heart disease, nonfatal myocardial infarction, stroke, and hospitalization for unstable angina (hazard ratio [HR] 1.25, 95% CI 1.09–1.44, \( P = 0.001 \)) as well as all-cause mortality (HR 1.58, 95% CI 1.14–2.19, \( P = 0.006 \)) compared with placebo after 12 months. This was despite torcetrapib increasing HDL-C by 72% and decreasing LDL-C by 25%. The worrisome results of ILLUMINATE were paralleled by negative imaging findings in trials in which coronary and carotid
ultrasonography were used (78, 79). These negative findings have been at least partly attributed to the off-target effects of torcetrapib, such as the raising of systolic blood pressure by an average of 5.4 mmHg. As suggested by aldosterone measurements from participants in ILLUMINATE (77), findings from animal models (80) and human adrenal cell assays (81) suggest these off-target effects may be related to stimulation of aldosterone synthesis by torcetrapib via pathways independent of CETP inhibition.

Could inhibition of CETP activity explain some of the adverse effects observed in the clinical development program of torcetrapib? Initial concerns about CETP inhibition highlighted the possibility that the formation of large cholesterol-rich HDL particles resulting from CETP inhibition might be associated with impaired cholesterol efflux from peripheral macrophages to these particles (82). However, studies of patients either deficient in CETP or treated with a CETP inhibitor demonstrated not reduced, but rather enhanced, efflux of cholesterol via ABCG1 to HDL-C (83, 84). Thus, an important step of reverse cholesterol transport remains intact, if not improved, in the setting of CETP inhibition.

On the other hand, the net effect of CETP inhibition on reverse cholesterol transport might depend, in part, on the effects of CETP on
the hepatic uptake of HDL-derived cholesterol. The hepatic uptake of HDL-C can be direct, or occur after transfer of HDL-C via CETP to apo B-containing lipoproteins, which are then taken into the liver via the LDL receptor. As illustrated by macrophage-specific reverse cholesterol transport assays, in the setting of highly effective LDL clearance, CETP can actually enhance reverse cholesterol transport and have an atheroprotective role. However, when LDL clearance is impaired, CETP can slow down reverse cholesterol transport and thus be proatherogenic (85). The interdependence of terminal reverse cholesterol transport pathways suggests that individuals who are most likely to benefit from CETP inhibition are those with suboptimal LDL-receptor-mediated hepatic uptake of cholesterol.

Fortunately, at least two novel compounds apparently lacking the off-target effects of torcetrapib enable further testing of the CETP-inhibition strategy, namely dalcetrapib and anacetrapib.

**Dalcetrapib:** Dalcetrapib binds CETP irreversibly and is considerably less-potent than torcetrapib (86). A study in a hamster model suggested that dalcetrapib promotes reverse cholesterol transport (87). In a human study, among individuals with mean baseline HDL-C and LDL-C levels of 47 mg/dl and 144 mg/dl, respectively, mono-therapy with 600 mg of dalcetrapib daily increased HDL-cholesterol
levels by 23% compared with placebo administration, after 4 weeks of
treatment (88). Among patients with type II dyslipidemia receiving 40 
mg of pravastatin daily and whose baseline levels of HDL-C and LDL-C 
were 48 mg/dl and 120 mg/dl, respectively, the addition of 600 mg of 
dalcetrapib daily increased HDL-cholesterol levels by 28% and 
decreased LDL-cholesterol levels by 7% compared with placebo 
administration, after 4 weeks of treatment (89). After 24 weeks of 
therapy with 900 mg of dalcetrapib daily, HDL-C levels increased by 
33% (mean baseline level of 42 mg/dl) in patients at high risk of 
coronary heart disease events who were treated with 10–80 mg of 
atorvastatin daily, when compared with HDL levels in participants 
receiving placebo plus atorvastatin (90). LDL-C levels, however, did not 
differ in the two patient groups (mean baseline level of 74 mg/dl). 
Importantly, no changes in blood pressure or aldosterone levels were 
observed with the use of high-dose dalcetrapib (900 mg).

Dal-PLAQUE (91) was a phase IIb, double-blind trial conducted at 11 
centers in patients with CHD or CHD risk equivalents, treated with 
LDL-C lowering drugs to LDL-C <100 mg/dL (<2.6 mmol/L). Patients 
were randomized to dalcetrapib 600 mg or placebo daily for 24 
months, with a 2-week safety follow-up. Endpoints included indices of 
plaque burden from the right and left carotid and abdominal aorta 
determined by magnetic resonance imaging (MRI) after 24 months,
and plaque inflammation using 18F-fluoro-deoxyglucose uptake measured by positron emission tomography/computed tomography (PET/CT) after 6 months. 189 subjects were screened and 130 randomized into the trial. Based on MRI, a significant reduction in total vessel area and a trend towards reduction in average wall area were observed with dalcetrapib vs. placebo after 24 months (-4.01 mm² [-7.23, -0.80]; p=0.041 and -2.20 mm² [-4.54, 0.13]; p=0.120 respectively). Other indices of plaque burden were numerically reduced from baseline with dalcetrapib versus placebo. Based on PET/CT, mean of maximum standardized uptake value and target to background ratio were unchanged with dalcetrapib versus placebo after 6 months. HDL-C increased by 31% with dalcetrapib after 24 months with no significant increases in inflammatory biomarkers. Dalcetrapib was well tolerated with a safety profile similar to placebo and was not associated with an increase in blood pressure.

Dal-PLAQUE 2 (92) will also assess changes in atherosclerotic plaque (morphology, composition, and inflammatory activity) among patients with CHD treated with 600 mg of dalcetrapib daily.

Dal-VESSEL (93) was an exploratory phase IIb randomized, double-blind, placebo-controlled trial in patients with CHD or CHD risk equivalents, in which 476 patients with HDL-C levels <50 mg/dL were
recruited. They received dalcetrapib 600 mg/day or placebo in addition to their existing treatments. The primary efficacy endpoint was change from baseline in brachial flow mediated dilation after 12 weeks. The primary safety endpoint was 24-hour ambulatory blood pressure monitoring assessed at week four. Patients were treated for a total period of 36 weeks. Results showed that dalcetrapib reduced CETP activity by almost 50% and increased HDL-C levels by 31% without changing nitric-oxide-dependent endothelial function or markers of inflammation and oxidative stress. Dalcetrapib did not increase 24-hour ambulatory blood pressure (ABPM) at week 4, the primary safety endpoint.

Finally, the phase III clinical trial Dal-Outcomes (94) will evaluate the effects of adding 600 mg of dalcetrapib daily to optimum pharmacotherapy in patients with acute coronary syndrome over a 2 year follow up period, with results expected in 2013.

Anacetrapib: Anacetrapib inhibits CETP by forming a tight reversible bond (95). Healthy individuals with mean baseline HDL-C and LDL-C of 51 mg/dl and 138 mg/dl, respectively after receiving 300 mg of anacetrapib daily for 10 days showed increases in HDL-C by 129% and decreases in LDL-C by 38% (96). No changes in blood pressure, assessed through 24 h ambulatory monitoring, were observed. Among
patients with dyslipidemia who had mean baseline HDL-C and LDL-C of 50 mg/dl and 141 mg/dl, respectively, addition of 300 mg of anacetrapib to 20 mg of atorvastatin daily for 8 weeks increased HDL-C by 120% and decreased LDL-C by 30% compared with statin monotherapy (97). Interestingly, lipoprotein (a) levels, which were unchanged by statin therapy, decreased by 50% following anacetrapib administration.

The phase III Determining the Efficacy and Tolerability of CETP Inhibition with Anacetrapib (DEFINE) randomized, placebo-controlled trial examined the effect of 100 mg of anacetrapib administered daily for 18 months to 1623 CHD or CHD equivalent patients who had achieved LDL-C treatment goals with statin therapy (98). The primary end points were the percent change in LDL-C at 24 weeks and the safety profile of anacetrapib at 76 weeks. HDL-C and other lipid parameters including lipoprotein (a) were assessed as secondary endpoints (94). Treatment with anacetrapib was associated with a 40% reduction in LDL-C from 81 mg/dl to 45 mg/dl \((P < 0.001)\) and a 138% increase in HDL-C from 41 mg/dl to 101 mg/dl \((P < 0.001)\) compared with placebo. Lipoprotein (a) decreased 36% compared with placebo from 27 nmol/l to 15 nmol/l. No increases in clinic-based blood pressure, serum aldosterone levels, or cardiovascular events were observed following anacetrapib treatment at 76 weeks.
these substantial improvements in LDL-C, HDL-C, and lipoprotein (a), as well as an apparently benign safety profile, the Randomized EValuation of the Effects of Anacetrapib Through Lipid-modification (REVEAL) is scheduled to begin in April 2011(100). This study will examine major coronary events in 30,000 patients with coronary heart disease, cerebrovascular atherosclerotic disease, or peripheral artery disease (see Table 3).

**Agonists of the Liver X Receptor**

Liver X receptors (LXRs), which are members of the nuclear receptor superfamily, have a central role in lipid metabolism. Endogenously activated by oxysterols, LXRs regulate the transcription of a myriad of target genes by binding to their promoters together with the retinoic acid receptor (101). With regard to HDL and reverse cholesterol transport, LXR activation has been demonstrated to promote mobilization of intracellular cholesterol (102), increase macrophage cholesterol efflux via macrophage ABCA1 and ABCG1 (103), and augment intestinal HDL generation (104). Therapeutic development of LXR agonists has been hindered by hepatic steatosis and increased plasma triglyceride concentrations reported in preclinical studies of these drugs (105).

**Endothelial lipase inhibitors**
Synthesized by and bound to vascular endothelial cells, endothelial lipase exhibits predominant phospholipase activity and affinity for HDL, unique characteristics among the lipoprotein-lipase family (106). An association between the expression of endothelial lipase and HDL-cholesterol levels was identified in overexpression and loss-of-function mouse models (107-109). Genetic studies indicate a similar association in humans, with rare and low-frequency loss-of-function variants of endothelial lipase, identified through deep sequencing, resulting in elevated HDL-cholesterol levels (110). How changes in HDL-cholesterol levels attributed to endothelial lipase ultimately affect atherosclerosis remains uncertain. Some human studies point to an atherogenic role of endothelial lipase, with a positive association between plasma levels of this enzyme and coronary artery calcification, features of the metabolic syndrome (such as impaired fasting glucose, and waist circumference), and inflammation (111,112). Carriers of endothelial-lipase variants associated with raised HDL-cholesterol levels have been reported to have a decreased risk of atherothrombotic disease,(113) although this link has not been observed in other studies (114,115). Of note, animal studies have shown that HDL-cholesterol levels do not always correlate with physiological changes associated with decreased atherosclerotic burden, with an endothelial-lipase knockout mouse model failing to demonstrate improved macrophage reverse cholesterol transport with
raised HDL-cholesterol levels (116). More worrisome, in the setting of hepatic-lipase deficiency, is that the absence of endothelial lipase resulted in an accumulation of small dense LDL,(116) a particularly atherogenic subpopulation of LDL. These findings suggest that endothelial-lipase inhibition could potentially exert a detrimental effect on atherosclerosis, even though HDL-cholesterol levels are raised. Despite this uncertainty, endothelial lipase has been the object of substantial interest as a therapeutic target. High-throughput screening identified several compounds sharing a sulfonl furan urea core as potent and selective endothelial-lipase inhibitors (117). Further evaluation of these and other small-molecule inhibitors of endothelial lipase has not been performed yet.

**Conclusions**

Targeting HDL-C is an integral component of the management of CHD and risk reduction. Several strategies can be used to increase HDL-C levels to target cardiovascular risk reduction, including pharmacologic management focused on the use of statin, statin combination therapy, and investigational drugs targeting HDL-C metabolism and reverse cholesterol transport. However, the negative results obtained from the ILLUMINATE and AIM-HIGH clinical trials suggest that improving HDL-C levels in plasma alone does not necessarily translate into cardiovascular risk reduction. Due to the complexity of HDL cholesterol
metabolism and the wide variety of targets for improving HDL cholesterol levels, it is clear that further research is needed to determine which will be the safest, most cost-effective, and most efficacious for reducing both rates of atherogenesis and risk for acute cardiovascular events. Ongoing and future clinical trials will comprehensively evaluate these HDL cholesterol-raising therapies in patients in both the primary and secondary prevention settings.
REFERENCES

   Dallas (TX): American Heart Association; 2012.

   Circulation 2006;113:2363e72.

3. Duffy D, Rader DJ. Update on strategies to increase HDL quantity and function.

5. Davidson MH. Focus on HDL as a therapeutic target for CAD risk reduction. Am J Cardiol 2009;104(Suppl 10):1Ee2E.


9. Fazio S, Linton MF. Elevated high-density lipoprotein (HDL) levels due to hepatic lipase mutations do not reduce cardiovascular disease risk:


23. van der Steeg WA, Holme I, Boekholdt SM, et al. High-density lipoprotein cholesterol, high-density lipoprotein particle size, and


33. Vaughan AM, Oram JF. ABCA1 and ABCG1 or ABCG4 act sequentially to remove cellular cholesterol and generate cholesterol-rich HDL. J Lipid Res. 2006;47:2433–2443.


38. Davidson MH, Rosenson RS. Novel targets that affect high-density lipoprotein metabolism: the next frontier. Am J Cardiol 2009;104(10 Suppl):52Ee7E.


44. Guyton JR, Bays HE. Safety considerations with niacin therapy. Am J Cardiol 2007; 99:22C-31C.


76. Tall AR. The effects of cholesterol ester transfer protein inhibition on cholesterol efflux. Am J Cardiol 2009;104(Suppl):39Ee45E.


93. ClinicalTrials.gov. A study assessing the effect of RO4607381 on vascular function in patients with coronary heart disease (CHD)
orCHD-risk equivalent patients [online],

94. ClinicalTrials.gov. A study of RO4607381 in stable coronary heart
disease patients with recent acute coronary syndrome [online],

95. Ranalletta, M. et al. Biochemical characterization of cholesteryl

96. Krishna, R. et al. Effect of the cholesteryl ester transfer protein
inhibitor, anacetrapib, on lipoproteins in patients with dyslipidaemia
and on 24-h ambulatory blood pressure in healthy individuals: two
double-blind, randomised placebo-controlled phase I studies. Lancet

97. Bloomfield, D. et al. Efficacy and safety of the cholesteryl ester
transfer protein inhibitor anacetrapib as monotherapy and
coadministered with atorvastatin in dyslipidemic patients. Am. Heart J.


104. Brunham, L. R. et al. Intestinal ABCA1 directly contributes to HDL


<table>
<thead>
<tr>
<th>Drug Class</th>
<th>HDL-C Increase</th>
<th>Mechanism of Action</th>
<th>Side Effects</th>
<th>Clinical Trial Results</th>
</tr>
</thead>
<tbody>
<tr>
<td>Statins</td>
<td>5%-15%</td>
<td>3-hydroxy-3-methyl-glutaryl-CoA reductase (HMG-CoA) inhibitor</td>
<td>Myopathy, Increased liver enzymes.</td>
<td>Reduced major coronary events, CAD deaths, need for coronary procedures, stroke and total mortality</td>
</tr>
<tr>
<td>Niacin</td>
<td>15%-35%</td>
<td>Decreased clearance of ApoA1</td>
<td>Flushing, hepatotoxicity, hyperuricemia, upper gastrointestinal distress, hyperglycemia</td>
<td>Reduced major coronary events</td>
</tr>
<tr>
<td>Fibrates</td>
<td>10%-20%</td>
<td>Peroxisome proliferator-activated receptor-alpha (PPAR-α) agonist</td>
<td>Dyspepsia, gallstones, myopathy</td>
<td>Reduced major coronary events</td>
</tr>
</tbody>
</table>
**Table 2: HDL-directed pharmacotherapeutic strategies**

**Directly augmenting apo A-1**

Intravenous apo A-1 therapy
- Recombinant apoA-1 Milano/phospholipids (ETC-216)
- Purified native apoA-1/phospholipids (CSL-111/112)
- Autologous delipidated HDL

**Indirectly augmenting apo A-1**

- Oral upregulator of endogenous apoA-1 production (RVX-208)
- Niacin receptor (GPR109A) agonists

**Mimicking Apo A1 Functionality**

- Apo A-1 mimetic peptides

**Enhancing reverse cholesterol transport**

Cholesterol ester transfer protein inhibitors
- Dalcetrapib
- Anacetrapib

Liver X receptor agonists
Table 3: Ongoing late-stage clinical trials of HDL-directed therapies

<table>
<thead>
<tr>
<th>Drug</th>
<th>Trial</th>
<th>Patient population (n)</th>
<th>Anticipated completion date</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>CETP Inhibitors</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Dalcetrapib</td>
<td>DAL-Outcomes</td>
<td>Acute coronary syndromes (15,600)</td>
<td>2013</td>
</tr>
<tr>
<td>Anacetrapib</td>
<td>REVEAL</td>
<td>Stable coronary heart disease or risk equivalent (30,000)</td>
<td>2017</td>
</tr>
<tr>
<td><strong>Niacin</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Niacin-laropiprant</td>
<td>HPS2-THRIVE</td>
<td>Stable vascular disease (25,000)</td>
<td>2013</td>
</tr>
</tbody>
</table>
Figure 1: HDL metabolism and targets of therapeutic intervention. Synthesized by the liver and the intestine, apo A-I acquires phospholipid to form nascent preβ-HDL. ABCA1 initiates the first step of reverse cholesterol transport, facilitating the efflux of free cholesterol from peripheral cells to nascent preβ-HDL. LCAT esterifies the cholesterol molecules to form cholesteryl esters, which migrate to the core of the HDL particle, resulting in formation of α-HDL. These mature HDL particles can acquire additional lipid via efflux mediated by ABCG1 and SR-BI. CETP mediates exchanges of cholesteryl esters for triglycerides with VLDL or LDL, affecting depletion in cholesteryl esters and enrichment in triglycerides of HDL. The resulting HDL3 particles can be either taken up by the liver via SR-BI holoparticle uptake or modified by hepatic lipase and endothelial lipase. Metabolism by the latter releases lipopoor apo A-I, which can be filtered by the glomerulus and degraded by cubilin/megalin in the proximal renal tubule. Targets of HDL-directed therapeutic interventions are indicated by red arrows and lines. Abbreviations: ABC, ATP-binding cassette transporter; Apo A-I, apolipoprotein A-I; CETP, cholesteryl ester transfer protein; CD36 and LIMPII analogous-I; LCAT, lecithin-cholesterol acyltransferase; LDL-R, LDL receptor; SR-BI, scavenger receptor class B type I.
Figure 2. Algorithm for the management of low serum high-density lipoprotein (HDL) cholesterol. CAD - coronary artery disease; LDL - low-density lipoprotein.
lipoprotein; NCEP - National Cholesterol Education Program; TZD-thiazolidinedione. (Adapted from Circulation.22)